HC Wainwright Issues Negative Estimate for DRUG Earnings
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They ...
H.C. Wainwright says SEC plan to dismiss suit lifts ‘major overhang’ on Coinbase
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright Sticks to Its Hold Rating for Biotricity (BTCY)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...
Cleanspark Unusual Options Activity
Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...
Morningstar26d
H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker
Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...
2RDW : Spotlight on Redwire: Analyzing the Surge in Options Activity
Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we ...
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...
Business Wire26d
H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker
NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...
Investing13d
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...
Hosted on MSN23d
HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation
Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Surrozen (NasdaqCM:SRZN) with a Buy recommendation. Analyst Price Forecast Suggests 199.20% Upside As of December ...